Serum matrix metalloprotease-1 and vascular endothelial growth factor - A predict cardiac allograft rejection

American Journal of Transplantation

Volumn 9, Issue 1, 2009, Pages 149-159

  Aharinejad, S ^a   Krenn, K ^a,b   Zuckermann, A ^a   Schafer R ^a   Gmeiner, M ^a   Thomas, A ^a   Aliabadi, A ^a   Schneider, B ^b   Grimm, M ^a  

^a Medical University of Vienna   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiac allograft rejection; MMP 1; Prognosis; VEGF A

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CYCLOSPORIN A; EVEROLIMUS; INTERSTITIAL COLLAGENASE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; VASCULOTROPIN A;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; ENZYME BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETRANSPLANTATION; SENSITIVITY AND SPECIFICITY;

ADULT; BASE SEQUENCE; BLOTTING, WESTERN; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58049219022     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02470.x     Document Type: Article

References (41)

1. Taylor DO, Edwards LB, Boucek MM et al. International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: Twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 2006 25 : 869 879.
2. Stoica SC, Cafferty F, Pauriah M et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 2006 25 : 420 425.
3. Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005 24 : 1710 1720.
4. Mehra MR, Feller E, Rosenberg S. The promise of protein-based and gene-based clinical markers in heart transplantation: From bench to bedside. Nat Clin Pract Cardiovasc Med 2006 3 : 136 143.
5. Deng MC, Eisen HJ, Mehra MR et al. CARGO Investigators. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006 6 : 150 160.
6. Mehra MR, Kobashigawa JA, Deng MC et al. CARGO Investigators. Transcriptional signals of T-cell and corticosteroid-sensitive genes are associated with future acute cellular rejection in cardiac allografts. J Heart Lung Transplant 2007 26 : 1255 1263.
7. Mehra MR, Kobashigawa JA, Deng MC et al. CARGO Investigators. Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection. J Heart Lung Transplant 2008 27 : 297 301.
8. Nwakanma LU, Williams JA, Weiss ES, Russel SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 2007 84 : 1556 1563.
9. Starling RC, Pham M, Valantine H et al. Working Group on Molecular Testing in Cardiac Transplantation. Molecular testing in the management of cardiac transplant recipients: Initial clinical experience. J Heart Lung Transplant 2006 25 : 1389 1395.
10. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996 156 : 1 4.
11. Aharinejad S, Krenn K, Zuckermann A et al. Matrix metalloproteases and their tissue inhibitor in cardiac transplantation. Eur J Cardiothorac Surg 2007 32 : 48 51.
12. Suzuki J, Isobe M, Kawauchi M, Endoh M, Amano J, Takamoto S. Altered expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in acutely rejected myocardium and coronary arteriosclerosis in cardiac allografts of nonhuman primates. Transpl Int 2000 13 : 106 113.
13. Tsukioka K, Suzuki J, Kawauchi M et al. Expression of membrane-type 1 matrix metalloproteinase in coronary vessels of allotransplanted primate hearts. J Heart Lung Transplant 2000 19 : 1193 1198.
14. Hariya A, Takazawa K, Yamamoto T, Amano A. ONO-4817, a novel matrix metalloproteinase inhibitor, attenuates allograft vasculopathy in a rat cardiac transplant. J Heart Lung Transplant 2004 23 : 1163 1169.
15. Campbell LG, Ramachandran S, Liu W et al. Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. Am J Transplant 2005 5 : 517 528.
16. Eaton VL, Lerret NM, Velásquez-Lopera MM et al. Enhanced allograft survival and modulation of T-cell alloreactivity induced by inhibition of MMP/ADAM enzymatic activity. Am J Transplant 2008 8 : 507 516.
17. Abramson LP, Pahl E, Huang L et al. Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation. Transplantation 2002 73 : 153 156. Erratum 73 : 321.
18. Reinders ME, Fang JC, Wong W, Ganz P, Briscoe DM. Expression patterns of vascular endothelial growth factor in human cardiac allografts: Association with rejection. Transplantation 2003 76 : 224 230.
19. Lemström KB, Krebs R, Nykänen AI et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 2002 105 2524 2530.
20. Raisky O, Nykänen AI, Krebs R et al. VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts. Arterioscler Thromb Vasc Biol 2007 27 : 819 825.
21. Wood KJ. Passenger leukocytes and microchimerism: What role in tolerance induction? Transplantation 2003 75 : 17S 20S.
22. Kanno S, Wu YJ, Lee PC et al. Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation 2001 104 : 934 938.
23. Miura M, Morita K, Kobayashi H et al. Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol 2001 167 : 3494 3504.
24. Nathan MJ, Mold JE, Wood SC et al. Requirement for donor and recipient CD40 expression in cardiac allograft rejection: Induction of Th1 responses and influence of donor-derived dendritic cells. J Immunol 2004 172 : 6626 6633.
25. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996 156 : 3952 3960.
26. Mach F, Schonbeck U, Fabunmi RP et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: Implications for tubule formation. Am J Pathol 1999 154 : 229 238.
27. de Groot-Kruseman HA, Baan CC, Loonen EH et al. Failure to down-regulate intragraft cytokine mRNA expression shortly after clinical heart transplantation is associated with high incidence of acute rejection. J Heart Lung Transplant 2001 20 : 503 510.
28. de Groot-Kruseman HA, Mol WM, Niesters HG et al. Differential intragraft cytokine messenger RNA profiles during rejection and repair of clinical heart transplants. A longitudinal study. Transpl Int 2003 16 : 9 14.
29. Michaels PJ, Kobashigawa J, Laks H et al. Differential expression of RANTES chemokine, TGF-beta, and leukocyte phenotype in acute cellular rejection and quilty B lesions. J Heart Lung Transplant 2001 20 : 407 416.
30. Ferri C, Properzi G, Tomassoni G et al. Patterns of myocardial endothelin-1 expression and outcome after cardiac transplantation. Circulation 2002 105 : 1768 1771.
31. Aharinejad S, Krenn K, Paulus P et al. Differential role of TGF-beta1/bFGF and ET-1 in graft fibrosis in heart failure patients. Am J Transplant 2005 5 : 2185 2192.
32. Aharinejad S, Taghavi S, Klepetko W, Abraham D. Prediction of lung-transplant rejection by hepatocyte growth factor. Lancet 2004 363 : 1503 1508.
33. Schoels M, Dengler TJ, Richter R, Meuer Sc, Giese T. Detection of cardiac allograft rejection by real-time PCR analysis of circulating mononuclear cells. Clin Transplant 2004 18 : 513 517.
34. Lacraz S, Isler P, Vey E, Welgus HG, Dayer JM. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 1994 269 : 22027 22033.
35. Chalasani G, Li Q, Konieczny BT et al. The allograft defines the type of rejection (acute versus chronic) in the face of an established effector immune response. J Immunol 2004 172 : 7813 7820.
36. Aharinejad S, Schäfer R, Krenn K et al. Donor myocardial HIF-1alpha is an independent predictor of cardiac allograft dysfunction: A 7-year prospective, exploratory study. Am J Transplant 2007 7 : 2012 2019.
37. Eisen HJ, Tuzcu EM, Dorent R et al. RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003 349 : 847 858.
38. Hartmann B, Schmid G, Graeb C et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: A novel approach for tailored immunosuppressive therapy. Kidney Int 2005 68 : 2593 2598.
39. Brenneisen P, Wenk J, Wlaschek M, Krieg T, Scharffetter-Kochanek K. Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. J Biol Chem 2000 275 : 4336 4344.
40. Evans RW, Williams GE, Baron HM et al. The economic implications of non-invasive molecular testing for cardiac allograft rejection. Am J Transplant 2005 5 : 1553 1558.
41. Bonaros N, Dunkler D, Kocher A et al. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation. J Heart Lung Transplant 2006 25 : 1154 1163.